

Translation

Chugai Debuts on Dow Jones Sustainability Asia Pacific Index, an Index for Socially Responsible Investment

September 19, 2014 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] (hereafter “Chugai”) announced that it has been selected for the first time as an index component of the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific). This index is the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which is one of the world’s premier indices for Socially Responsible Investment (SRI).

The DJSI is a leading SRI index, jointly compiled by S&P Dow Jones Indices LLC of the United States and RobecoSAM AG of Switzerland, which serves as one of the most important indices for investors who take into consideration the corporate social responsibility (CSR) initiatives of each company. Leading sustainability-driven companies are selected as the index components every year based on the assessment in terms of long-term economic, environmental, and social criteria. The DJSI Asia Pacific is specifically designed for companies in the developed Asia Pacific markets including Japan. This year, 148 companies were selected, including 65 Japanese companies, which are leading the way in terms of sustainability, among the 600 companies in the region.

For selection of the companies as the index components of DJSI Asia Pacific, RobecoSAM AG assesses companies based on questionnaire responses and information from public sources such as Annual Reports and websites. Chugai participated in the assessment from this year, and won the inclusion in DJSI Asia Pacific at the first time as a result of its proactive activities based on the three criteria above. F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan], a parent company of Chugai, received the highest scores within the Pharmaceuticals, Biotechnology & Life Sciences Industry and has been recognized as the Group Leader in the DJSI for the sixth consecutive year.

In addition to the DJSI Asia Pacific, Chugai has also been continuously included since 2003 as an index component of FTSE4Good Global Index, which is also a global SRI index selected by FTSE International Limited (FTSE) and Ethical Research Services Limited (EIRIS).

Based on the business philosophy of “Innovation all for the patients,” Chugai is committed to actively fulfill our social responsibilities as a healthcare company, by adding exceptional value through the creation of innovative medical products and services for the benefit of the medical community and human health around the world.